Education
About Us
Working with TipRanks
Follow Us
Hookipa Pharma Inc (HOOK)
OTHER OTC:HOOK
HOOK Stock Chart & Stats
$0.89
$0.01(0.53%)
At close: 4:00 PM EST
$0.89
$0.01(0.53%)
Day’s Range― - ―
52-Week Range$0.72 - $2.80
Previous CloseN/A
Volume38.61K
Average Volume (3M)15.71K
Market Cap
$11.01M
Enterprise Value-$17.83M
Total Cash (Recent Filing)$34.23M
Total Debt (Recent Filing)$546.00K
Price to Earnings (P/E)―
Beta1.96
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,930,789
10 Day Avg. Volume21,467
30 Day Avg. Volume15,706
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.49
Price to Sales (P/S)0.57
P/FCF Ratio-0.33
Enterprise Value/Market Cap-1.62
Enterprise Value/Revenue-1.20
Enterprise Value/Gross Profit-1.20
Enterprise Value/Ebitda0.33
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Corporate RestructuringPoolbeg shareholders are expected to receive 0.03 shares of Hookipa for each Poolbeg share, resulting in approximately 55% of the equity of the combined entity.
Bears Say
Financial StabilityHookipa had approximately $60M in cash, which is believed to be insufficient to support the company to realize meaningful value inflection points from its own pipeline.
Shareholder DilutionHookipa plans to raise approximately $30M through a primary private placement, which is expected to lead to significant dilution for current Hookipa shareholders.
Hookipa Pharma News
HOOK FAQ
What was Hookipa Pharma Inc’s price range in the past 12 months?
Hookipa Pharma Inc lowest stock price was $0.72 and its highest was $2.80 in the past 12 months.
What is Hookipa Pharma Inc’s market cap?
Hookipa Pharma Inc’s market cap is $11.01M.
When is Hookipa Pharma Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hookipa Pharma Inc’s earnings last quarter?
Currently, no data Available
Is Hookipa Pharma Inc overvalued?
According to Wall Street analysts Hookipa Pharma Inc’s price is currently Overvalued.
Does Hookipa Pharma Inc pay dividends?
Hookipa Pharma Inc does not currently pay dividends.
What is Hookipa Pharma Inc’s EPS estimate?
Hookipa Pharma Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hookipa Pharma Inc have?
Hookipa Pharma Inc has 9,930,789 shares outstanding.
What happened to Hookipa Pharma Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hookipa Pharma Inc?
Currently, no hedge funds are holding shares in HOOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hookipa Pharma Inc
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
Technical Analysis
Kazia Therapeutics
―
Phio Pharmaceuticals
―
Windtree Therapeutics
―
BiomX
―
Polyrizon Ltd.
―
Ownership Overview
1.11% Insiders
0.05% Mutual Funds
3.23% Other Institutional Investors
95.61% Public Companies and
Individual Investors